FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897691818> ?p ?o ?g. }

• W2897691818 endingPage "150" @default.
• W2897691818 startingPage "146" @default.
• W2897691818 abstract "Abstract Integrase interactor 1 (INI-1)-deficient carcinoma is a rare cancer characterized by the loss of the SWItch/Sucrose Non-Fermentable-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 gene (SMARCB1) and tends to follow an aggressive clinical course. There is no currently available standard therapy option, although a few promising treatment strategies, including enhancer of zeste homolog 2 (EZH2) inhibition, are under active investigation. This report describes a 30-year-old woman with INI-1-deficient carcinoma who progressed on combination chemotherapy and an EZH2 inhibitor. Next-generation-sequencing-based targeted cancer-related gene assay confirmed SMARCB1 loss and revealed other mutations in breast cancer 1 gene and checkpoint kinase 2 gene, which may have impacted her clinical course. After discussion at the molecular tumor board, she was offered alisertib, an aurora A kinase inhibitor, on a single-patient expanded-use program and achieved prolonged disease stabilization. Aurora A kinase inhibition may have an important role in the management of patients with INI-1-deficient tumors, warranting further evaluation in clinical studies. Key Points Loss of the SWItch/Sucrose Non-Fermentable-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 gene (SMARCB1), which encodes integrase interactor 1 (INI-1), is associated with various mesenchymal malignancies, but a few carcinomas with rhabdoid features have been recently described as a distinct entity. INI-1-deficient carcinoma can be very aggressive, and there is no known treatment option available. There are encouraging preliminary data with an enhancer of zeste homolog 2 inhibitor, tazematostat, in INI-1-deficient malignancies, including INI-1-deficient carcinomas. Loss of INI-1 can activate aurora A kinase (AurkA), and inhibition of AurkA by alisertib could be a viable option and warrants further investigation in this cancer. Clinical genomic profiling can confirm diagnosis of molecularly defined malignancy and provide insights on therapeutic options." @default.
• W2897691818 created "2018-10-26" @default.
• W2897691818 creator A5008997964 @default.
• W2897691818 creator A5015338103 @default.
• W2897691818 creator A5029130433 @default.
• W2897691818 creator A5036452213 @default.
• W2897691818 creator A5039216029 @default.
• W2897691818 creator A5042094291 @default.
• W2897691818 creator A5068928585 @default.
• W2897691818 creator A5071669347 @default.
• W2897691818 date "2018-10-08" @default.
• W2897691818 modified "2023-10-14" @default.
• W2897691818 title "Clinical Benefit to an Aurora A Kinase Inhibitor in a Patient with Metastatic Integrase Interactor 1-Deficient Carcinoma" @default.
• W2897691818 cites W1989996784 @default.
• W2897691818 cites W2007171597 @default.
• W2897691818 cites W2008769862 @default.
• W2897691818 cites W2026789216 @default.
• W2897691818 cites W2036230897 @default.
• W2897691818 cites W2063150104 @default.
• W2897691818 cites W2063851753 @default.
• W2897691818 cites W2068077839 @default.
• W2897691818 cites W2068638854 @default.
• W2897691818 cites W2083352151 @default.
• W2897691818 cites W2101910636 @default.
• W2897691818 cites W2102317602 @default.
• W2897691818 cites W2122722975 @default.
• W2897691818 cites W2171249466 @default.
• W2897691818 cites W2233319314 @default.
• W2897691818 cites W2254315911 @default.
• W2897691818 cites W2343896049 @default.
• W2897691818 cites W2513820391 @default.
• W2897691818 cites W2538686606 @default.
• W2897691818 cites W2565755851 @default.
• W2897691818 cites W2574827531 @default.
• W2897691818 cites W2578843483 @default.
• W2897691818 cites W2742436583 @default.
• W2897691818 cites W2785484811 @default.
• W2897691818 cites W2793108944 @default.
• W2897691818 doi "https://doi.org/10.1634/theoncologist.2018-0279" @default.
• W2897691818 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6369939" @default.
• W2897691818 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30297384" @default.
• W2897691818 hasPublicationYear "2018" @default.
• W2897691818 type Work @default.
• W2897691818 sameAs 2897691818 @default.
• W2897691818 citedByCount "3" @default.
• W2897691818 countsByYear W28976918182019 @default.
• W2897691818 countsByYear W28976918182020 @default.
• W2897691818 countsByYear W28976918182022 @default.
• W2897691818 crossrefType "journal-article" @default.
• W2897691818 hasAuthorship W2897691818A5008997964 @default.
• W2897691818 hasAuthorship W2897691818A5015338103 @default.
• W2897691818 hasAuthorship W2897691818A5029130433 @default.
• W2897691818 hasAuthorship W2897691818A5036452213 @default.
• W2897691818 hasAuthorship W2897691818A5039216029 @default.
• W2897691818 hasAuthorship W2897691818A5042094291 @default.
• W2897691818 hasAuthorship W2897691818A5068928585 @default.
• W2897691818 hasAuthorship W2897691818A5071669347 @default.
• W2897691818 hasBestOaLocation W28976918181 @default.
• W2897691818 hasConcept C104317684 @default.
• W2897691818 hasConcept C111936080 @default.
• W2897691818 hasConcept C167227067 @default.
• W2897691818 hasConcept C177450382 @default.
• W2897691818 hasConcept C50171091 @default.
• W2897691818 hasConcept C502942594 @default.
• W2897691818 hasConcept C54355233 @default.
• W2897691818 hasConcept C71924100 @default.
• W2897691818 hasConcept C83640560 @default.
• W2897691818 hasConcept C86339819 @default.
• W2897691818 hasConcept C86803240 @default.
• W2897691818 hasConceptScore W2897691818C104317684 @default.
• W2897691818 hasConceptScore W2897691818C111936080 @default.
• W2897691818 hasConceptScore W2897691818C167227067 @default.
• W2897691818 hasConceptScore W2897691818C177450382 @default.
• W2897691818 hasConceptScore W2897691818C50171091 @default.
• W2897691818 hasConceptScore W2897691818C502942594 @default.
• W2897691818 hasConceptScore W2897691818C54355233 @default.
• W2897691818 hasConceptScore W2897691818C71924100 @default.
• W2897691818 hasConceptScore W2897691818C83640560 @default.
• W2897691818 hasConceptScore W2897691818C86339819 @default.
• W2897691818 hasConceptScore W2897691818C86803240 @default.
• W2897691818 hasIssue "2" @default.
• W2897691818 hasLocation W28976918181 @default.
• W2897691818 hasLocation W28976918182 @default.
• W2897691818 hasLocation W28976918183 @default.
• W2897691818 hasLocation W28976918184 @default.
• W2897691818 hasOpenAccess W2897691818 @default.
• W2897691818 hasPrimaryLocation W28976918181 @default.
• W2897691818 hasRelatedWork W2097445405 @default.
• W2897691818 hasRelatedWork W2508232108 @default.
• W2897691818 hasRelatedWork W2603189030 @default.
• W2897691818 hasRelatedWork W2903905383 @default.
• W2897691818 hasRelatedWork W2943249495 @default.
• W2897691818 hasRelatedWork W2945230928 @default.
• W2897691818 hasRelatedWork W2951196122 @default.
• W2897691818 hasRelatedWork W2994127519 @default.
• W2897691818 hasRelatedWork W3007150393 @default.
• W2897691818 hasRelatedWork W4237388850 @default.
• W2897691818 hasVolume "24" @default.

• next